Phase II Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ
Status:
Active, not recruiting
Trial end date:
2025-10-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, controlled, open-label study comparing perioperative
atezolizumab with FLOT chemotherapy versus FLOT alone in patients with locally advanced,
operable adenocarcinoma of the stomach or GEJ.
Phase:
Phase 2
Details
Lead Sponsor:
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest